Uli Steidl

Dr. Steidl trained at the Harvard Stem Cell Institute and held a junior faculty position at Beth Israel Deaconess Medical Center prior to joining the Albert Einstein College of Medicine, where he is now a tenured Professor of Cell Biology and Medicine (Oncology), Program Leader at the NCI-designated Albert Einstein Cancer Center, and a faculty member of the Gottesman Institute for Stem Cell Research. Dr. Steidl’s work has pioneered mechanistic studies and target identification in pre-cancerous and leukemia stem cells, and has resulted in numerous high-profile publications, patents, preclinical development and testing of novel drugs, and clinical trials. Dr. Steidl’s research is supported by the NIH, NYSTEM, NYSCF, the Leukemia & Lymphoma Society, and several other private foundations. He has served as an advisor to numerous large pharma and small/mid sized biotech companies.